In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

The stock's fall snapped a seven-day winning streak.

Shares of BIIB opened at $150.38 on Friday. The company has a market capitalization of $22.01 billion, a P/E ratio of 13.44, a P/E/G ratio of 1.51 and a beta of 0.01. Biogen Inc. has a one year ...

WM Technology Inc (MAPS) recently held its Q1 2025 earnings call, revealing substantial revenue growth and strategic advancements. According to InvestingPro analysis, the company appears ...

After hours: March 12 at 7:57:29 PM EDT Loading Chart for BIIB ...

Pre-Market: 5:58:06 a.m. EDT Loading Chart for BIIB ...